Min Qiang1,2
Zhe Chen1
Hongyang Liu2
Junxue Dong3
Kejian Gong1Xinjun Zhang1Peng Huo4Jingjun Zhu5Yifeng Shao6Jinazun Ma1Bowei Zhang1
Wei Liu1*
Mingbo Tang1*- 1Department of Thoracic Surgery, The First Hospital of Jilin University, Changchun, China
- 2College of Clinical Medicine, Jilin University, Changchun, China
- 3Department of Molecular Biology, Max Planck Institute for Infection Biology, Berlin, Germany
- 4Laboratory of Infection Oncology, Institute of Clinical Molecular Biology, Christian-Albrechts-Universität zu Kiel and University Hospital Schleswig-Holstein, Kiel, Germany
- 5Department of Thoracic and Cardiovascular Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
- 6Department of General Surgery, Capital Institute of Pediatrics’ Children’s Hospital, Beijing, China
A Corrigendum on
Targeting the PI3K/AKT/mTOR pathway in lung cancer: mechanisms and therapeutic targeting
by Qiang M, Chen Z, Liu H, Dong J, Gong K, Zhang X, Huo P, Zhu J, Shao Y, Ma J, Zhang B, Liu W and Tang M (2025). Front. Pharmacol. 16:1516583. doi: 10.3389/fphar.2025.1516583
In the published article, there was an error in the Funding statement. The funding statement in the article is written incorrectly as “Jilin Provincial Science and Technology Development Plan Project, 20220204115YY.” The correct statement is “Jilin Province science and technology development plan project:YDZJ202301ZYTS007”. The correct Funding statement appears below.
Funding
The author(s) declare that financial support was received for the research and/or publication of this article. The study was supported by Jilin Province science and technology development plan project:YDZJ202301ZYTS007; Jilin Province Medical and Health Personnel Special Fund (JLSWSRCZX2023). The funding source provided financial support for the project but had no role in the study design, data collection, analysis, interpretation, or writing of the manuscript.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: PI3K/Akt/mTOR pathway, lung cancer, PI3K inhibitors, Akt inhibitors, mTOR inhibitors, natural products, combined therapy
Citation: Qiang M, Chen Z, Liu H, Dong J, Gong K, Zhang X, Huo P, Zhu J, Shao Y, Ma J, Zhang B, Liu W and Tang M (2025) Corrigendum: Targeting the PI3K/AKT/mTOR pathway in lung cancer: mechanisms and therapeutic targeting. Front. Pharmacol. 16:1591443. doi: 10.3389/fphar.2025.1591443
Received: 11 March 2025; Accepted: 31 March 2025;
Published: 24 April 2025.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2025 Qiang, Chen, Liu, Dong, Gong, Zhang, Huo, Zhu, Shao, Ma, Zhang, Liu and Tang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Wei Liu, bF93MDFAamx1LmVkdS5jbg==; Mingbo Tang, bWJ0YW5nQGpsdS5lZHUuY24=